抗体药物偶联物治疗非小细胞肺癌的研究进展和展望

Research progress and prospect of antibody-drug conjugates in the treatment of non-small cell lung cancer

抗体药物偶联物(ADC)代表一种新兴抗肿瘤治疗策略,融合了单克隆抗体的高度特异性和高细胞毒性药物的杀伤力。相对于传统化疗药物,ADC不仅能够精准识别肿瘤靶点,还能够实现药物快速传递到肿瘤细胞内,在降低全身毒副作用的同时提供更高的治疗效力。ADC已经在多种肿瘤类型中展现了出色的治疗效果,在非小细胞肺癌(NSCLC)中的应用也备受关注,本文就ADC在NSCLC治疗中的研究现状和前景进行综述。

Antibody-drug conjugates(ADCs)represent an emerging anticancer therapeutic strategy that combines the high specificity of monoclonal antibodies with the lethality of highly cytotoxic drugs to fully leverage the advantages of tar-geted therapies.Compared with traditional chemotherapy drugs,ADCs can not only accurately identify tumor targets,but al-so achieve rapid delivery of drugs into tumor cells,providing higher therapeutic efficacy while reducing systemic toxic side effects.ADCs have shown excellent therapeutic effect in a variety of cancer types,and its research and application in the treatment of non-small cell lung cancer has also attracted much attention.This paper reviews the research status and pros-pects of ADCs in the treatment of non-small cell lung cancer.